Dr Reddy’s Laboratories has launched Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA).
As per the regulatory filing, Albenza brand and generic had U.S. sales of approximately $27 million MAT for the most recent twelve months ending in November 2020 according to IQVIA Health*.
Dr Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.
Albenza is a trademark of Glaxosmithkline.
At around 2.17 pm, Dr Reddy's is trading at Rs5192.35 per piece up by Rs91 or 1.8% on Sensex.